BridgeMD
Tests treatment safety and results for Hepatic Encephalopathy
Official title Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
ClinicalTrials.gov ID: NCT04161053
What this study is testing
What is Rifaximin?
Rifaximin is an investigational medicine, given as an once-daily, being studied as a potential treatment for hepatic encephalopathy.
Also referred to as Gastrobiotic, Trencedia.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Efficacy and Safety of Nitazoxanide in preventing recurrence of Hepatic Encephalopathy.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 20 to 65
You may be able to join if
- Cirrhotic patient with at least one previous episode of hepatic encephalopathy.
- Adult Patients aging from 20 to 65 years old
You likely can't join if
- Active GIT bleeding.
- Major psychiatric illness (psychosis \& epilepsy).
- Renal insufficiency (S.Cr 2mg/dl).
The study team makes the final eligibility decision.
Where it's taking place
- Tanta, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 20 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Tanta, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.